Skip to main content
. Author manuscript; available in PMC: 2017 Sep 27.
Published in final edited form as: Oncogene. 2017 Mar 27;36(30):4299–4310. doi: 10.1038/onc.2017.64

Figure 6. Skp2 is essential for Twist-mediated CSC self-renewal and chemotherapy resistance.

Figure 6

(a, b) Tumor sphere formation assay of PC3 (a) or 22Rv1 (b) cells overexpressed with vector control and Twist. Scale bar represents 100 μm. (c) Tumor sphere formation assay of luciferase or Skp2-depleted 22Rv1 cells. Scale bar represents 100 μm. (d) Tumor sphere formation assay of PC3 cells overexpressed with vector control and Twist in the absence or presence of Skp2 inhibitor, compound #25. Scale bar represents 100 μm. (e, f) Cell growth inhibition assay of 22Rv1 cells with luciferase or Skp2 silencing treated with doxorubicin (e) or paclitaxel (f). (g) Cell growth inhibition assay of 22Rv1 cells treated with a combination of paclitaxel and compound #25. Quantified results are presented as means ± SD; *, p < 0.05 and **, p < 0.01.